The Impact of Interferon Beta 1a on Egyptian Relapse-Reemitting Multiple Sclerosis Patients

Our study aimed to investigate the effect of interferon beta 1a on the clinical and immunological parameters in Egyptian relapse-remitting multiple sclerosis patients

Inclusion Criteria:Age between 18 and 50 years at time of signing informed consent form.Relapsing- remitting multiple sclerosis as per the McDonald 2017 criteria, including an MRI brain satisfying the 2017 radiological criteria.Full-field visual evoked potential (VEP) P100 latency in at least one eye of ≥118 ms.Kurtzke EDSS step 0.0 - 6.0.At the time of screening, being treated with a stable dose for at least 6 months of a category 1 multiple sclerosis DMT or for at least 2 years with a category 2 DMT.Exclusion Criteria:they had been treated in the last 30 days with methylprednisolonethey had changed their IFN-β preparation within the last 18 monthsthey had other chronic diseases associated with MSthey had been previously treated with immunosuppressive agents